Among other things, the disclosure of the present invention is related to make pathology and cytology faster, better, and lower cost, as well as to using fast cytology to quickly determine the concentration of the analyte outside a cell in a sample. The present invention is also related to rapid intra-cellular assays.

The systems, methods, devices and kits disclosed herein be used to determine the presence and/or level a target analyte(s) in a biological sample, wherein the analyte(s) is associated with a pathogenic (e.g., a viral antigen or whole virus) or otherwise altered physiological condition (e.g., pregnancy). In certain embodiments, the systems, methods, devices and kits provide one or more improved properties relative to the RT-PCT and lateral flow antibody assays known in the art for the detection of SARS-CoV-2, including but not limited to, assay time, ease of use, risk of infection, accuracy, specificity, selectivity, limit of detection of the assay, quantitative detection and the effect of common interferents to the sensor output, cost, simplicity or a combination thereof.

Multimeric binding molecules that are capable of specifically binding to hemagglutinin (HA) of at least two influenza A virus strains, said strains comprising HA of two different HA subtypes from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza B virus strain are provided. The binding molecules preferably are also capable of neutralizing at least two influenza A virus strains from phylogenetic group 2; or capable of neutralizing at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically neutralizing at least one influenza B virus strain.

Disclosed herein are recombinant baculoviruses suitable for detecting the presence of arthropod-borne viruses in a biological sample of a test subject. The information derived from the detection may also be used to render a diagnosis on whether the test subject is infected with the arthropod-borne viruses or not, so that proper course of treatment may be assigned to the subject.

Embodiments of a recombinant Respiratory Syncytial Virus (RSV) G ectodomain are provided. Also disclosed are nucleic acids encoding the RSV G ectodomain and methods of producing the RSV G ectodomain. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for inhibiting a RSV infection in a subject by administering an effective amount of the recombinant RSV G ectodomain to the subject to produce a protective immune response.

The present invention methods and compositions for differentiating a Zika virus infection in a subject from infection by a different flavivirus.

The invention provides an isolated essentially mammalian positive-sense single stranded RNA virus classifiable as belonging to the Order: Nidovirales; Family: Coronaviridae; Subfamily: Coronavirinae; Genus: Betacoronavirus; and non-Lineage A, non-Lineage B or non-Lineage D, human betacoronavirus. The invention also provides a human virus having a receptor binding domain (RBD) capable of binding to a dipeptidyl peptidase 4. The invention also provides diagnostic means and methods, prophylactic means and methods and therapeutic means and methods to be employed in the diagnosis, prevention and/or treatment of disease, in particular of respiratory disease, in particular of mammals, more in particular in humans.

The invention is related to identification of an interferon-analog (IFNL4) protein and genetic association with spontaneous clearance of HCV infection and response to treatment for HCV infection.

The present invention is an antibody including an amino acid sequence, wherein the amino acid sequence includes, in an N- to C-direction, the following structural domains:

N-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4-C

wherein FR denotes a framework region amino acid sequence and CDR denotes a complementary determining region amino acid sequence; the CDR1 includes an amino acid sequence represented by GFTFSNY (SEQ ID NO: 1): the CDR2 includes an amino acid sequence represented by NSGGTG (SEQ ID NO: 2); and the CDR3 includes an amino acid sequence represented by RVDGRVLSTIVVSYDY (SEQ ID NO: 3). The antibody is capable of binding to an intranuclear protein of an influenza virus.

A method for a pre-symptomatic diagnosis of a viral illness in a subject is provided. The method may include obtaining a biological sample that includes at least one peripheral blood mononuclear cell from a subject prior to the subject experiencing any symptoms associated with the viral illness. The method may further include extracting proteins from the biological sample. The method may also include analyzing the extracted proteins, via mass spectrometry, for the presence of a predefined viral protein biomarker associated with the viral illness. If the predefined viral protein biomarker is present, the subject is diagnosed with the viral illness prior to experiencing the symptoms associated with the viral illness.